[1] 上官琳珏, 赵春雷.分化型甲状腺癌及其失分化机制的研究进展[J]. 癌症进展, 2019, 17(16):1861-1865.
[2] YUAN Q, LIU Y, FAN Y, et al. LncRNA HOTTIP promotes papillary thyroid carcinoma cell proliferation, invasion and migration by regulating miR-637[J]. International Journal of Biochemistry & Cell Biology, 2018, 98:1-9.
[3] DONNEM T, REYNOLDS A R, KUCZYNSKI E A, et al. Non-angiogenic tumours and their influence on cancer biology[J]. Nature Reviews Cancer, 2018, 18(5):323-336.
[4] 陈孝霞, 辜臻晟.细胞因子在角膜新生血管和淋巴管生成中效应研究[J]. 中国实用眼科杂志, 2017, 35(6):558-562.
[5] WU D, GAO Y, QI Y, et al. Peptide-based cancer therapy:opportunity and challenge[J]. Cancer Letters, 2014, 351(1):13-22.
[6] CHANG Y W, SU C M, SU Y H, et al. Novel peptides suppress VEGFR-3 activity and antagonize VEGFR-3-mediated oncogenic effects[J]. Oncotarget, 2014, 5(11):3823-3835.
[7] WU X, HUANG H, WANG C, et al. Identification of a novel peptide that blocks basic fibroblast growth factor-mediated cell proliferation[J]. Oncotarget, 2013, 4(10):1819-1828.
[8] WU D, TIAN W, LI J, et al. Peptide P11 suppresses the growth of human thyroid carcinoma by inhibiting the PI3K/AKT/mTOR signaling pathway[J]. Molecular Biology Reports, 2019, 46(3):2665-2678.
[9] 秦宝山, 郭云霞, 韩莉.微小RNA-215-5p靶向eIF2a负向调控结肠癌细胞增殖[J]. 东南大学学报(医学版), 2020, 39(6):780-787.
[10] ZHAO C, LI Y, ZHANG M, et al. miR-126 inhibits cell proliferation and induces cell apoptosis of hepatocellular carcinoma cells partially by targeting Sox2[J]. Human Cell, 2015, 28(2):91-99.
[11] KIM M K, JUNG S B, KIM J S, et al. Expression of microRNA miR-126 and miR-200c is associated with prognosis in patients with non-small cell lung cancer[J]. Virchows Archiv, 2014, 465(4):463-471.
[12] KITANO M, RAHBARI R, PATTERSON E E, et al. Expression profiling of difficult-to-diagnose thyroid histologic subtypes shows distinct expression profiles and identify candidate diagnostic microRNAs[J]. Annals of Surgical Oncology, 2011, 18(12):3443-3452.
[13] AMR K S, ABDELMAWGOUD H, ALI Z Y, et al. Potential value of circulating microRNA-126 and microRNA-210 as biomarkers for type 2 diabetes with coronary artery disease[J]. British Journal of Biomedical Science, 2018, 75(2):82-87.
[14] DU C, LV Z, CAO L, et al. miR-126-3p suppresses tumor metastasis and angiogenesis of hepatocellular carcinoma by targeting LRP6 and PIK3R2[J]. Journal of Translational Medicine, 2014, 12(1):259-269.
[15] PERÖBNER I, KAROW M, JOCHUM M, et al. LRP6 mediates Wnt/β-catenin signaling and regulates adipogenic differentiation in human mesenchymal stem cells[J]. The International Journal of Biochemistry & Cell Biology, 2012, 44(11):1970-1982.
[16] 范文强, 姬宇宙, 刘先本.癌蛋白LRP6调节FGF8信号对肺癌细胞增殖的影响研究[J]. 癌症进展, 2018, 16(5):54-57.
[17] 张毅, 钟自彪, 叶启发, 等.微小RNA-202可通过转录后下调低密度脂蛋白受体相关蛋白6的表达抑制人肝癌细胞增殖[J]. 中华实验外科杂志, 2015, 32(9):2154-2156.
[18] MA C, LUO C, YIN H, et al. Kallistatin inhibits lymphangiogenesis and lymphatic metastasis of gastric cancer by downregulating VEGF-C expression and secretion[J]. Gastric Cancer, 2018, 21(4):617-631.
[19] JOINER D M, KE J, ZHONG Z, et al. LRP5 and LRP6 in development and disease[J]. Trends in Endocrinology and Metabolism, 2012, 24(1):31-39. |